With the demand for human breast milk on the rise, there exists a greater potential for contamination. A recent study found bovine contamination in over 10% of the breast milk samples tested. This technology detects bovine milk contamination in human breast milk.
A need exists for a device capable of preventing accidental injuries during oral surgery. This technology provides a disposable device designed to protect a patient’s lips from lacerations and burns.
The Ohio State and Nationwide Children's Hospital Vaccine Consortium: Mark Peeples, PhD, Nationwide Children's Hospital
The Ohio State and NCH Vaccine Consortium is an interconnected group of six expert virologists in human infection and immune response, genetic manipulation of viruses, and small animal vaccine testing. We have made major progress toward converting the current experimental respiratory syncytial virus (RSV) live attenuated vaccine into a functional, economically viable vaccine candidate. We have also developed, and continue to develop vaccines to protect livestock from diseases that threaten their economic viability.
Ultra-Violet Disinfection Lighting: Siddharth Rajan, PhD, The Ohio State University
Current sanitation procedures for surgical tools, hospital beds and equipment, water and air filtration systems, and the like, are costly, inefficient, and not environmentally friendly. Ultra-Violet Sanitation lighting effectively breaks down bacteria, viruses, mold and more, however, the cost of UV Sanitation is not feasible for most companies. Instead of using mercury lamps, this technology uses quantum mechanical tunneling to increase efficiency while reducing the cost of UV lighting by 50 times the average price.
Magnetic Resonance Elastography (MRE): Arun Kolipaka, PhD, The Ohio State University
Magnetic resonance elastography (MRE) is a new application of MRI technology that employs sound waves and gives the physician an estimate of the stiffness of body tissues via a visual map. MRE has found its first application in the diagnosis of liver disease. This invention offers the promise of extending MRE to other organs such as the heart, pancreas, prostate and spleen.
Novel Therapy for Scarring: David Brigstock, PhD, Nationwide Children's Hospital
There are currently no FDA-approved treatments for fibrosis, a pathological condition central to a variety of debilitating and potentially life-threatening disorders. This technology utilizes naturally-occurring cellular products called exosomes to reprogram fibrotic cells for treatment of liver fibrosis.
The showcase featured a keynote speaker, six health science technology presentations followed by a networking and poster viewing session. The diverse portfolio of technologies featured represents many different areas of the health sciences industry—software, imaging, probiotics, and more.
2:00 PM - Introduction & Welcome
2:10 PM - Technology Showcase
2:10 – 2:30 pm
Novel Probiotic Formulations
Steven Goodman, PhD - Nationwide Children’s Hospital
In various disease states, especially in the gut, lack of sufficient probiotic bacteria is problematic. Dr. Goodman describes a novel method and formulation to introduce probiotic strains of bacteria to a site with enhanced efficiency and durability.
2:30 – 2:50 pm
A.C.T.I.V.E.: Movement assessments across the lifespan using the Microsoft Kinect™
Linda Lowes, PhD - Nationwide Children’s Hospital
This technology represents a cost effective and powerful video-based assessment tool for movement in infants.
2:50 – 3:10 pm
MatchTx: A Treatment Match Platform for Personalized Cancer Therapy
James Chen, MD - The Ohio State University
Current treatment for cancer is often a case of trial-and-error, with physicians unable to predict a patient’s response to a particular therapy. MatchTx is a software platform that calculates the patient’s response to a given cancer treatment regimen. Using similarity-based prediction algorithms, MatchTx adapts treatment decisions based on previous patient outcomes. With MatchTx in a Bench-top prototype stage it was validated in prostate cancer and Liposarcoma.
3:10 PM - Break
3:30 PM - Technology Showcase
3:30 – 3:50 pm
Electromagnetic Detection and Localized Imaging of Cancer
Vishwanath Subramaniam, PhD - The Ohio State University
Dr. Subramaniam, in conjunction with faculty in the colleges of Engineering and Medicine, has developed a suite of Electromagnetic (EM) technologies that have the potential to positively impact significant health challenges in today’s world. These technologies have resulted in low cost devices that have shown efficacy in cancer imaging; metastasis of cells; wound healing; malaria detection.
3:50 – 4:10 pm
Developing Therapies for the Treatment of Rare & Orphan Diseases
Tim Miller, PhD, President & CEO, Abeona Therapeutics Nationwide Children’s Hospital
Based on technology developed at Nationwide Children's Hospital, Abeona Therapeutics is focused on developing a cure for Sanfilippo Syndrome, a rare genetic disorder caused by the body’s inability to properly break down certain sugars.
4:10 – 4:30 pm
System for Site & Disease-Specific Remote Optimization of MRI Image Quality
Jinghua Wang, PhD & Zhong-Lin Lu, PhD - The Ohio State University
Doctors Wang and Lu present three low-cost, bundled techniques to maximize MRI image quality based on the current scanner environment. The optimizations are substantially automated, can be performed remotely from a central location, and are directed to each particular situation, addressing a site’s specific MRI hardware, a disease type and age group of interest, as well as individual patient images.
4:30 PM - Break
4:40 PM - Keynote Speaker: Joe Hernandez, MS, MBA, Founder, Chairman & CEO of Microlin Bio
5:10 PM - Reception & Networking
The 2013 Technology Showcase was held Thursday, March 14, 2013, at The Research Institute at Nationwide Children's Hospital. The showcase was sponsored by BioOhio and TechColumbus.
1:00-1:30 PM: Networking Reception
1:30-3:30 PM: Technology Showcase
1:30-1:35 PM: Introduction
1:35-2:55 PM: Presentations
2:55-3:00 PM: Break
3:00 to 3:30 PM: Keynote Speaker
About the Speaker
Dr. David Scholl served as President and CEO of Diagnostic Hybrids, Inc. (DHI) in Athens, Ohio from 1995 to 2009. One of DHI’s early technology founders, Dave joined the company as Director of Research in 1983. Under his leadership, DHI grew from a four-person startup to the Inc. 500 list, emerging as a world leader in cell- and MAb-based diagnostics. The company’s dynamic growth led to its sale in February 2010 to Quidel Corporation of San Diego, California. Dave then joined the Quidel executive team as a Senior Vice President, while remaining President of DHI until his retirement in October 2011. He is now a partner with Athenian Venture Partners, a venture capital firm that makes investments in private, high growth potential, technology based companies in the Information Technology and Biomedical Sciences sphere.
Dave currently serves on the boards of the Ohio Third Frontier Commission, BioOhio, Ohio University’s Edison Biotechnology Institute and Manasseh Cutler Scholars Program, and served from 2006-2012 as president of the Foundation for Ichthyosis and Related Skin Types (FIRST). He is also a trustee of Ohio University and the Ohio University Foundation.
Dave has nearly 30 years of life sciences experience in research and development, executive management and venture capital. In 2003, he was the recipient of the Central Ohio Ernst and Young Entrepreneur of the Year Award in Life Sciences, in 2006 was awarded BioOhio's Bioscience Leadership Award, and in 2010, Dave was awarded The Phillips Medal of Public Service by the Ohio University Heritage College of Osteopathic Medicine, and in 2013 named an inaugural recipient of The Konneker Medal for Innovation and Entrepreneurship by Ohio University.